UNLIMITED TURBO BULL - NOVO-NORDISK B | Market Closed - Euronext Paris 07:02:23 03/05/2024 BST | ||
| 8.66 EUR | -1.59% |
|
| Current month | -2.55% | ||
| 1 month | +0.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/05/24 | 8.66 | -1.59% | 1 |
| 02/05/24 | 8.8 | -2.55% | 103 |
| 30/04/24 | 9.03 | +1.46% | 97 |
| 29/04/24 | 8.9 | -0.78% | 87 |
| 26/04/24 | 8.97 | +3.46% | 89 |
Real-time Euronext Paris
Last update May 03, 2024 at 07:02 am
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| 686XS | |
| ISIN | DE000SF0CC83 |
| Date issued | 17/05/2021 |
| Strike | 221.4 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.57 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.8 € |
|---|---|
| Lowest since issue | 0.555 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
873.1
DKK
Average target price
906.2
DKK
Spread / Average Target
+3.79%
- Stock Market
- Certificates
- 686XS Certificat
